Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2025 value amounting to 0.85%.

  • Seres Therapeutics' Return on Capital Employed fell 1500.0% to 0.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.58% for FY2024, which is 1800.0% up from last year.
  • Per Seres Therapeutics' latest filing, its Return on Capital Employed stood at 0.85% for Q3 2025, which was down 1500.0% from 0.89% recorded in Q2 2025.
  • Seres Therapeutics' 5-year Return on Capital Employed high stood at 0.14% for Q3 2021, and its period low was 1.08% during Q3 2022.
  • Its 5-year average for Return on Capital Employed is 0.58%, with a median of 0.57% in 2021.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -9400bps in 2022, then skyrocketed by 8600bps in 2023.
  • Seres Therapeutics' Return on Capital Employed (Quarter) stood at 0.22% in 2021, then crashed by -234bps to 0.74% in 2022, then skyrocketed by 47bps to 0.39% in 2023, then crashed by -165bps to 1.03% in 2024, then rose by 17bps to 0.85% in 2025.
  • Its Return on Capital Employed was 0.85% in Q3 2025, compared to 0.89% in Q2 2025 and 0.95% in Q1 2025.